The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
(2012) In Nature Reviews Clinical Oncology 9(10). p.579-590- Abstract
- Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that... (More)
- Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3184309
- author
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Nature Reviews Clinical Oncology
- volume
- 9
- issue
- 10
- pages
- 579 - 590
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000309550800010
- scopus:84867099700
- pmid:22949046
- ISSN
- 1759-4782
- DOI
- 10.1038/nrclinonc.2012.150
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Hematology/Transplantation (013022014)
- id
- e3559261-6d75-4b45-9a5d-4fdfa8c1eb19 (old id 3184309)
- date added to LUP
- 2016-04-01 10:29:37
- date last changed
- 2022-08-20 03:21:21
@article{e3559261-6d75-4b45-9a5d-4fdfa8c1eb19, abstract = {{Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach.}}, author = {{Cornelissen, Jan J. and Gratwohl, Alois and Schlenk, Richard F. and Sierra, Jorge and Bornhaeuser, Martin and Juliusson, Gunnar and Racil, Zdenek and Rowe, Jacob M. and Russell, Nigel and Mohty, Mohamad and Lowenberg, Bob and Socie, Gerard and Niederwieser, Dietger and Ossenkoppele, Gert J.}}, issn = {{1759-4782}}, language = {{eng}}, number = {{10}}, pages = {{579--590}}, publisher = {{Nature Publishing Group}}, series = {{Nature Reviews Clinical Oncology}}, title = {{The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach}}, url = {{https://lup.lub.lu.se/search/files/1889047/3737313.pdf}}, doi = {{10.1038/nrclinonc.2012.150}}, volume = {{9}}, year = {{2012}}, }